1459 |
Taking DES Technology from Concept to Clinical Proof |
Eberhard Grube |
May. 15. 12 |
1458 |
Are Asian Patients Different? BioMatrix FlexTM Experience in Regional Settings |
Teguh Santoso |
May. 15. 12 |
1457 |
Very Long-term Outcomes with Biolimus A9¢â from an All-comers RCT: LEADERS 4 Year Data |
Stephan Windecker |
May. 15. 12 |
1456 |
Statin Benefit in Atherosclerosis: Focus on Asian Population |
Hiroyoshi Yokoi |
May. 15. 12 |
1455 |
The Ideal Patient Types for the Different Antiplatelet Agents |
Kyung Woo Park |
May. 15. 12 |
1454 |
Tailoring Antiplatelet Therapy for the Different Types of ACS-PCI Patients |
Adnan Kastrati |
May. 15. 12 |
1453 |
For High Risk ACS Patients, Early Use of GPI - Tirofiban |
Yongwhi Park |
May. 15. 12 |
1452 |
The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS |
Alan C. Yeung |
May. 15. 12 |
1451 |
A Scientific and Rational Approach to Delineate Future Stent Platforms |
Stephen Wai Luen Lee |
May. 15. 12 |
1450 |
COMBO - A Combination Sirolimus Eluting and Anti-CD34 Antibody Coated Stent: Technology, Development and Clinical Data |
Stephen Rowland |
May. 15. 12 |